Home / News
ASCO 2026
FDA Launches AEMS for Adverse Event Data
On March 11, the FDA launched AEMS, a unified platform designed to modernize how adverse event data is collected, analyzed, and shared. A step toward greater transparency in drug safety monitoring.
April 3, 2026
All FDA Approvals
All Cancer Types Endometrial Cancer Hematologic Malignancies Leukemia Lymphoma Multiple Myeloma Non-Small Cell Lung Cancer Prostate Cancer
All Diagnostics + Biomarkers Screening
All Therapeutic Approaches Chemotherapy Immunotherapy Targeted Therapy
News

FDA Launches AEMS for Adverse Event Data

April 3, 2026
  • 1
  • 2

What are you looking for?

Popular Searches

Oncology Practice Management Navigation